Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'

Akhtar, Naseem; Khan, Riaz A.

doi:10.1016/j.plipres.2016.08.005

Cited by 51 publications

(18 citation statements)

References 299 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 Transporters can reduce the side effect of some drugs when loaded. 47,76,77 There is also some evidence of possible dosage reduction when drugs are transported by liposomes. 78 These vesicles possess an important role in the delivery of substances into the skin, especially for lipophilic compounds.…”

Section: Liposomes As Transportersmentioning

confidence: 99%

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

Castañeda-Reyes

Perea-Flores

Dávila-Ortíz

et al. 2020

IJN

View full text Add to dashboard Cite

The skin is the largest organ in the human body, providing a barrier to the external environment. It is composed of three layers: epidermis, dermis and hypodermis. The most external epidermis is exposed to stress factors that may lead to skin conditions such as photo-aging and skin cancer. Some treatments for skin disease utilize the incorporation of drugs or bioactive compounds into nanocarriers known as liposomes. Liposomes are membranes whose sizes range from nano to micrometers and are composed mostly of phospholipids and cholesterol, forming similar structures to cell membranes. Thus, skin treatments with liposomes have lower toxicity in comparison to traditional treatment routes such as parenteral and oral. Furthermore, addition of edge activators to the liposomes decreases the rigidity of the bilayer structure making it deformable, thereby improving skin permeability. Liposomes are composed of an aqueous core and a lipidic bilayer, which confers their amphiphilic property. Thus, they can carry hydrophobic and hydrophilic compounds, even simultaneously. Current applications of these nanocarriers are mainly in the cosmetic and pharmaceutic industries. Nevertheless, new research has revealed promising results regarding the effectiveness of liposomes for transporting bioactive compounds through the skin. Liposomes have been well studied; however, additional research is needed on the efficacy of liposomes loaded with bioactive peptides for skin delivery. The objective of this review is to provide an up-to-date description of existing techniques for the development of liposomes and their use as transporters of bioactive compounds in skin conditions such as melanoma and skin inflammation. Furthermore, to gain an understanding of the behavior of liposomes during the process of skin delivery of bioactive compounds into skin cells.

show abstract

Section: Liposomes As Transportersmentioning

confidence: 99%

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

Castañeda-Reyes

Perea-Flores

Dávila-Ortíz

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…To use the GelMA‐based PEDOT/PSS hydrogels as a drug carrier for treatment of skin cancer, the fabricated hydrogels were loaded with 5‐fluorouracil (5‐FU), because 5‐FU has been used for treatment of various skin diseases for about half a century and also there are some studies about transdermal delivery of 5‐FU in the literature as well . Although 5‐FU indications approved by the United States Food and Drug Administration are actinic keratosis and superficial basal cell carcinoma, studies have shown that 5‐FU is also effective on the treatment of dermatological diseases such as squamous cell carcinoma in situ , warts, nail psoriasis, keratoacanthoma, and vitiligo . The interaction between drug and polymeric matrix is thought to originate from hydrogen bonds that can occur between the NH 2 and OH functional groups on gelatin and the NH, CO, CN, and CF side groups on 5‐FU …”

Section: Introductionmentioning

confidence: 99%

“…2,3 Although 5-FU indications approved by the United States Food and Drug Administration are actinic keratosis and superficial basal cell carcinoma, studies have shown that 5-FU is also effective on the treatment of dermatological diseases such as squamous cell carcinoma in situ, warts, nail psoriasis, keratoacanthoma, and vitiligo. 24,25 The interaction between drug and polymeric matrix is thought to originate from hydrogen bonds that can occur between the NH 2 and OH functional groups on gelatin and the N H, C O, C N, and C F side groups on 5-FU. 26 Electrically releasing of 5-FU from the GelMA-PEDOT/PSS hydrogel was examined under two different voltages (0 and 1.5 V) in pH 5.5 buffer solution to stimulate skin cancer conditions.…”

Section: Introductionmentioning

confidence: 99%

Electrically controlled release of 5‐fluorouracil from conductive gelatin methacryloyl‐based hydrogels

Oktay

Alemdar

2018

J of Applied Polymer Sci

View full text Add to dashboard Cite

Herein, electro‐responsive hydrogels were obtained by incorporation of poly(3,4‐ethylenedioxythiophene)/poly(styrenesulfonate) (PEDOT/PSS) into the gelatin methacryloyl (GelMA) by using photopolymerization technique. Hydrogels were characterized by FTIR and scanning electron microscopy analyses. Cytotoxicity tests were performed by L929 cell lines to determine cell compatibility. Swelling tests were conducted to investigate the water uptake capacity of hydrogels. 5‐fluorouracil (5‐FU) was selected as a model drug as it is known as a topical drug for some skin cancer type treatment. The release of 5‐FU from the hydrogel was provided in efficient and controlled manner at simulated skin cancer (pH = 5.5) and under 0 and 1.5 V. The simulated drug delivery experiments conducted in vitro revealed that the drug releasing amount was higher when voltage is applied to the hydrogels. All results visualized that the obtained GelMA‐based PEDOT/PSS hydrogels with enhanced electrical properties could be a potential candidate as an electrically sensitive drug carrier for treatment of skin cancer in the future applications. © 2018 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019, 136, 46914.

show abstract

“…Thus, it is critical to develop new medications for the treatment of OP with better curative outcomes, limited side effects, and increased safety . Recently, nucleic acid therapy—the use of siRNA and microRNA—has emerged as a novel strategy for disease treatment, such as cancer . Based on the available data, miR‐141 has recently been regarded as a tumor inhibitor in many cancer types, including glioma, thyroid cancer, ovarian cancer, gastric cancer, and breast cancer .…”

Section: Introductionmentioning

confidence: 99%

Suppression of Bone Resorption by miR-141 in Aged Rhesus Monkeys

Yang

Zhang

Cai

et al. 2018

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Aging-related osteoporosis (OP) is considered a serious public health concern. Approximately 30% of postmenopausal women suffer from OP; more than 40% of them risk fragility fractures. Multiple drugs have been prescribed to treat OP, but they are not ideal because of low cure rates and adverse side effects. miRNA-based gene therapy is a rapidly developing strategy in disease treatment that presents certain advantages, such as large-scale production capability, genetic safety, and rapid effects. miRNA drugs have been used primarily in cancer treatments; they have not yet been reported as candidates for osteoclast-targeted-OP treatment in primates. Their therapeutic efficacy has been limited by several shortcomings, such as low efficiency of selective delivery, insufficient expression levels in targeting cells, and unexpected side effects. Here, we identify miR-141 as a critical suppressor of osteoclastogenesis and bone resorption. The expression levels of miR-141 are positively correlated with BMD and negatively correlated with the aging of bones in both aged rhesus monkeys (Macaca mulatta) and osteoporotic patients. Selective delivery of miR-141 into the osteoclasts of aged rhesus monkeys via a nucleic acid delivery system allowed for a gradual increase in bone mass without significant effects on the health and function of primary organs. Furthermore, we found that the functional mechanism of miR-141 resides in its targeting of two osteoclast differentiation players, Calcr (calcitonin receptors) and EphA2 (ephrin type-A receptor 2 precursor). Our study suggests that miRNAs, such as miR-141, could play a crucial role in suppressing bone resorption in primates and provide reliable experimental evidence for the clinical application of miRNA in OP treatment. © 2018 American Society for Bone and Mineral Research.

show abstract

Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'

Cited by 51 publications

References 299 publications

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

<p>Development, Characterization and Use of Liposomes as Amphipathic Transporters of Bioactive Compounds for Melanoma Treatment and Reduction of Skin Inflammation: A Review</p>

Electrically controlled release of 5‐fluorouracil from conductive gelatin methacryloyl‐based hydrogels

Suppression of Bone Resorption by miR-141 in Aged Rhesus Monkeys

Contact Info

Product

Resources

About